Moderna wants to extent its European footprint
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital has launched a new life sciences fund with initial capital commitments of 50m and a target size of 150m.
European investment firm LSP has closed its European life sciences fund LSP at 1 bn. Additionally, a 10bn fund of funds was greenlighted at the EU Council in Paris.
AiCuris will pay up to 100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
AGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide 10bn for late-state tech companies.
Ribbon Biolabs has cashed in 18m in Series A financing led by Hadean Ventures
German mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.